|
1) 堀池典生, 村田洋介, 滝川 一, 他. 薬物性肝障害の実態—全国集計—. In: 恩地森一, 監修. 滝川 一, 福井 博, 堀池典生, 編. 薬物性肝障害の実態. 東京: 中外医学社; 2008. p. 1-10
|
|
|
|
|
2) Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injury in Japan—an analysis of 1, 676 cases between 1997 and 2006. Hepatol Res. 2009; 39: 427-31
|
|
|
|
|
3) Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32: 55-68
|
|
|
|
|
|
4) Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135: 1924-34
|
|
|
|
|
|
5) Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis. 2008; 28: 175-87
|
|
|
|
|
|
6) Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: Summary of a workshop. Hepatology. 2008; 47: 1401-15
|
|
|
|
|
|
7) Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: Analysis of the united network for organ sharing database. Liver Transpl. 2009; 15: 719-29
|
|
|
|
|
|
8) Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009; 49: 2001-9
|
|
|
|
|
|
9) Onji M, Fujioka S, Takeuchi Y, et al. Clinical characteristics of drug-induced liver injury in the elderly. Hepatol Res. 2009; 36: 546-52
|
|
|
|
|
|
10) Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008; 47: 2003-9
|
|
|
|
|
|
11) Gupta NK, Lewis JH. The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008; 28: 1021-41
|
|
|
|
|
|
12) Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007; 46: 1453-63
|
|
|
|
|
|
13) Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174: 935-52
|
|
|
|
|
|
14) Papay JI, Clines D, Rafi R, et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009; 54: 84-90
|
|
|
|
|
|
15) Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009; 50: 511-7
|
|
|
|
|
|
16) Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology. 2009; 49: 250-7
|
|
|
|
|
|
17) Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol. 2008; 14: 6999-7004
|
|
|
|
|
|
18) Stickel F, Droz S, Patsenker E, et al. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol. 2009; 50: 111-7
|
|
|
|
|
|
19) Lucena MI, Andrade RJ, Martínez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology. 2008; 48: 588-96
|
|
|
|
|
|
20) Lucena MI, Andrade RJ, Martínez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Author reply. Hepatology. 2008; 49: 1777-8
|
|
|
|
|
|
21) Watanabe I, Tomita A, Shimizu M, et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2003; 73: 435-55
|
|
|
|
|
|
22) Ueda K, Ishitsu T, Seo T, et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics. 2007; 8: 435-42
|
|
|
|
|
|
23) Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2008; 12: 994-1002
|
|
|
|
|
|
24) Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B＊5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009; 41: 816-9
|
|
|
|
|
|
25) Young B, Squires K, Patel P, et al. First large, multicenter, open-label study utilizing HLA-B＊5701 screening for abacavir hypersensitivity in North America. AIDS. 2008; 22: 1673-5
|
|
|
|
|
|
26) Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008？ Expert Opin Drug Metab Toxicol. 2009; 5: 843-60
|
|
|
|
|
|
27) Arrizabalaga J, Rodriguez-Alcántara F, Castañer JL, et al. Prevalence of HLA-B＊5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials. 2009; 10: 48-51
|
|
|
|
|
|
28) Park WB, Choe PG, Song KH, et al. Should HLA-B＊5701 screening be performed in every ethnic group before starting abacavir？ Clin Infect Dis. 2009; 48: 365-7
|
|
|
|
|
|
29) Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008; 9: 1617-22
|
|
|
|
|
|
30) Kurosaki M, Takagi H, Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci. 2000; 45: 1103-8
|
|
|
|
|
|
31) Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008; 8: 29-33
|
|
|
|
|
|
32) Pachkoria K, Lucena MI, Crespo E, et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol. 2008; 49: 107-14
|
|
|
|
|
|
33) Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008; 48: 1175-83
|
|
|
|
|
|
34) Takikawa H. Recent status of drug-induced liver injury. Hepatol Res. 2009; 39: 1-6
|
|
|
|
|
|
35) Suzuki A, Yuen N, Walsh J, et al. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol. 2009; 7: 882-8
|
|
|
|
|
|
36) Grieco A, Miele L, Forgione A, et al. Mild hepatitis at recommended doses of acetaminophen in patients with evidence of constitutionally enhanced cytochrome P450 system activity. J Clin Pharm Ther. 2008; 33: 315-20
|
|
|
|
|
|
37) Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006; 296: 87-93
|
|
|
|
|
|
38) Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009; 106: 4402-7
|
|
|
|
|
|
39) Masson MJ, Carpenter LD, Graf ML, et al. Pathogenic role of natural killer T and natural killer cells in acetaminophen-induced liver injury in mice is dependent on the presence of dimethyl sulfoxide. Hepatology. 2008; 48: 889-97
|
|
|
|
|
|
40) Jaeschke H. Innate immunity and acetaminophen-induced liver injury: Why so many controversies？ Hepatology. 2008; 48: 699-701
|
|
|
|
|
|
41) Nakagawa H, Maeda S, Hikiba Y, et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology. 2008; 135: 1311-21
|
|
|
|
|
|
42) Reisman SA, Buckley DB, Tanaka Y, et al. CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol Appl Pharmacol. 2009; 236: 109-14
|
|
|
|
|
|
43) Imaeda AB, Watanabe A, Sohail MA, et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest. 2009; 119: 305-14
|
|
|
|
|
|
44) Hu B, Colletti LM. Stem cell factor and c-kit are involved in hepatic recovery after acetaminophen-induced liver injury in mice. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G45-53
|
|
|
|
|